Oct 07, 2021 / 01:00PM GMT
Operator
Good day, and thank you for standing by, and welcome to the ORIC Pharmaceuticals Business Update Conference Call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Dominic Piscitelli, Chief Financial Officer. Please go ahead.
Dominic G. Piscitelli - ORIC Pharmaceuticals, Inc. - CFO
Good morning, and welcome to the ORIC Pharmaceuticals Business Update, AACR-NCI-EORTC Conference Call. This morning, we issued a press release highlighting initial clinical and translational data from our ongoing Phase Ib trial of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer as well as preclinical data on ORIC-114 in HER2-positive breast cancer.
You may find the press release posted on the Investor page of oricpharma.com. We have per-recorded our prepared remarks, after which we will host a live Q&A session. So please bear with us if we have any technical difficulties.
Before we begin, starting on Slide 2. During this conference call, we will be making forward-looking
Oric Pharmaceuticals Inc at AACR-NCI-EORTC Virtual International Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot